Premium
Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases *
Author(s) -
ZENG Min De,
FAN Jian Gao,
LU Lun Gen,
LI You Ming,
CHEN Cheng Wei,
WANG Bing Yuan,
MAO Yi Min
Publication year - 2008
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/j.1751-2980.2008.00331.x
Subject(s) - medicine , general surgery
Nonalcoholic fatty liver disease (NAFLD) is a clinical and pathological syndrome. The main characteristic is diffuse ballooning fatty degeneration of hepatocytes induced by pathologic factors except alcohol and other known factors that injure liver. NAFLD includes simple fatty liver and nonalcoholic steatohepatitis (NASH) with or without liver cirrhosis. Insulin resistance and genetic susceptibility are closely correlated with NAFLD. Following the greatly increased incidence of obesity and diabetes, NAFLD has become one of the common chronic diseases in our country, severely harming the people’s health. For standardizing the diagnosis, treatment and therapeutic effect evaluation of NAFLD, the Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Society of Hepatology organized experts in this field to work out guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases (abbreviated to ‘guidelines’) with reference to the latest worldwide research data and in accordance with the principles of evidence-based medicine. The evidence base categorized into three grades and five levels (Table 1), presented as italicized Rome digits in parentheses. 1